Recent Updates
Recently added Catalysts

parainfluenza virus type 3 vaccine

Phase 1

Respiratory Syncytial Virus Infection | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: Apr 23, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment390

FDA Designations

No designations recorded

Clinical trial landscape

parainfluenza virus type 3 vaccine · 1 trial · 3 indications

Phase 1 1
NCT06604767Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and OlderRespiratory Syncytial Virus Infection
COMPLETED390 Analytics
PHASE1COMPLETED
Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
Respiratory Syncytial Virus Infection
NCT06604767390
Unlock trial analytics

Study Endpoints

Primary Endpoints

Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each vaccination
Within 30 minutes after each vaccination

Number of participants experiencing immediate unsolicited systemic AEs

Presence of solicited administration site reactions within 7 days after vaccination
Within 7 days after vaccination

Number of participants reporting: \- injection site reactions: pain, erythema and swelling

Presence of solicited systemic reactions within 7 days after vaccination
Within 7 days after vaccination

Number of participants reporting: * systemic reactions: fever, headache, fatigue, myalgia, arthralgia and chills

Presence of unsolicited AEs within 28 days after vaccination
Within 28 days after vaccination

Number of participants experiencing unsolicited AEs

Presence of serious adverse events (SAEs)
Within 6 months after vaccination

Number of participants experiencing SAEs regardless of causality

Presence of adverse events of special interest (AESIs)
Within 6 months after vaccination

Number of participants experiencing AESIs regardless of causality

Presence of related SAEs throughout the study
Throughout the study, approximately 12 months

Number of participants experiencing related SAEs regardless of causality

Presence of related AESIs throughout the study
Throughout the study, approximately 12 months

Number of participants experiencing related AESIs regardless of causality

Presence of related fatal SAEs throughout the study
Throughout the study, approximately 12 months

Number of participants experiencing related fatal SAEs regardless of causality

Presence of out-of-range biological test results (including shift from baseline values)
Within 7 days after vaccination

Number of participants with biological safety assessment values out of normal range (as per the laboratory performing the test, including shift from baseline values)

Secondary Endpoints

RSV A serum neutralizing antibody (nAb) titers at pre-vaccination (Day 01) and post-vaccination (Day 29) in the RSV/hMPV +/- PIV3 and RSV vaccines
At Day 01 and Day 29
RSV B serum nAb titers at pre-vaccination (Day 01) and post-vaccination (Day 29) in the RSV/hMPV +/- PIV3 and RSV vaccines
At Day 01 and Day 29
hMPV A serum nAb titers at pre-vaccination (Day 01) and post-vaccination (Day 29) in the RSV/hMPV +/- PIV3 vaccines
At Day 01 and Day 29
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
PIV3 Dose 1EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1
PIV3 Dose 2EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1
PIV3 Dose 3EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1
PIV3 Dose 4EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1
RSV/hMPV /PIV3 Formulation 1EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1
RSV/hMPV Formulation 1EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1
RSV/hMPV Formulation 2EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1
RSV vaccine 1EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1
RSV vaccine 2EXPERIMENTALParticipants will receive a single intramuscular (IM) injection at Day 1

Interventions

NameTypeDescription
parainfluenza virus type 3 vaccine (PIV3)BIOLOGICALPharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular
RSV/hMPV/PIV3 vaccineBIOLOGICALPharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
RSV/hMPV vaccineBIOLOGICALPharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
RSV vaccine 1BIOLOGICALPharmaceutical form:Suspension for injection-Route of administration:Intramuscular
RSV vaccine 2BIOLOGICALPharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular
Unlock Study Design Details

Eligibility Criteria

Age Range60 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites8

Inclusion Criteria: * Aged 60 years or older on the day of inclusion (means from the means from the day of the 60th birthday). * Informed consent form (ICF) has been signed and dated * A female participant is eligible to participate if she is of non-childbearing potential. To be considered of non-c...

Countries:Australia
Unlock Eligibility Criteria

Frequently asked questions about parainfluenza virus type 3 vaccine

What is parainfluenza virus type 3 vaccine used for?

Parainfluenza virus type 3 vaccine is an investigational vaccine being studied for the prevention of respiratory syncytial virus (RSV) infection, as well as metapneumovirus and parainfluenza virus infections. It is currently in Phase 1 clinical development and is not yet approved for use.

Who makes parainfluenza virus type 3 vaccine?

Sanofi (ticker: SNY) is developing the parainfluenza virus type 3 vaccine. The vaccine is in Phase 1 clinical development for respiratory syncytial virus infection and related respiratory viral infections.

What phase is parainfluenza virus type 3 vaccine in?

Parainfluenza virus type 3 vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 1 trial has been completed.

What clinical trials is parainfluenza virus type 3 vaccine in?

Parainfluenza virus type 3 vaccine has one completed clinical trial, NCT06604767, which studied the vaccine candidate in adults aged 60 years and older. The trial enrolled 390 participants in Australia and evaluated the vaccine for respiratory syncytial virus, metapneumovirus, and parainfluenza virus infections.

Is parainfluenza virus type 3 vaccine the same as a respiratory syncytial virus vaccine?

Parainfluenza virus type 3 vaccine is a vaccine candidate that targets parainfluenza virus type 3, but it is being studied for its potential to protect against respiratory syncytial virus (RSV) infection as well. It is a combination vaccine candidate that also covers metapneumovirus and parainfluenza virus.